Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.

@article{Dennis2012BoneSI,
  title={Bone scan index: a quantitative treatment response biomarker for castration-resistant metastatic prostate cancer.},
  author={Elizabeth R. Dennis and Xiaoyu Jia and Irina S Mezheritskiy and Ryan Stephenson and Heiko Schoder and Josef J. Fox and Glenn Heller and Howard I. Scher and Steven M. Larson and Michael J Morris},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2012},
  volume={30 5},
  pages={519-24}
}
PURPOSE There is currently no imaging biomarker for metastatic prostate cancer. The bone scan index (BSI) is a promising candidate, being a reproducible, quantitative expression of tumor burden seen on bone scintigraphy. Prior studies have shown the prognostic value of a baseline BSI. This study tested whether treatment-related changes in BSI are prognostic for survival and compared BSI to prostate-specific antigen (PSA) as an outcome measure. PATIENTS AND METHODS We retrospectively examined… CONTINUE READING
53 Extracted Citations
11 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 53 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 11 references

Graphical methods for censored data

  • R Gentleman, J Crowley
  • J Am Stat Assoc 86:678-683,
  • 1991

The radiocolloid bone marrow scan in malignant disease

  • SM Larson, WB Nelp
  • J Surg Oncol 3:685-697,
  • 1971

Similar Papers

Loading similar papers…